BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
Portfolio Pulse from Lara Goldstein
BetterLife Pharma's non-hallucinogenic LSD derivative, BETR-001, is progressing through IND-enabling studies for Major Depressive Disorder. Braxia Scientific reports a 26.2% YoY growth in treatment volumes and plans to restructure its business, including slowing down its U.S.-based telemedicine business KetaMD.
June 09, 2023 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Braxia Scientific reports a 26.2% YoY growth in treatment volumes and plans to restructure its business, including slowing down its U.S.-based telemedicine business KetaMD.
Braxia Scientific's growth in treatment volumes is a positive sign, but the planned restructuring and slowdown of KetaMD could create uncertainty for investors. The overall impact on the stock price is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
BetterLife Pharma's BETR-001 is progressing through IND-enabling studies for Major Depressive Disorder, with clinical studies expected to begin after completion.
BetterLife Pharma's BETR-001 is progressing through IND-enabling studies, which is a positive sign for the company. If the clinical studies are successful, it could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100